Results round-up: S&N weak; HOLX, TFX, WMGI
This article was originally published in Clinica
Executive Summary
Women’s health firm Hologic beat analyst expectations in its second fiscal quarter and raised its guidance as new CEO Stephen MacMillan continues to make his mark on the company. Jefferies analyst Raj Denhoy noted the new chief has already carried out “significant cost cutting.” He also “gave more details around his strategy, which centers around investing for organic growth, no major asset sales but instead smaller divestitures, debt service, and lower tax rate.”